Figure 3
From: Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Comparison of OS for patients with cT1 triple-negative breast cancer between receiving NAC and upfront surgery + AC based on clinical T category. (A) Before PSM, OS of T1a; (B) Before PSM, OS of T1b; (C) Before PSM, OS of T1c; (D) Before PSM, BCSS of T1a; (E) Before PSM, BCSS of T1b; (F) Before PSM, BCSS of T1c; (G) After PSM, OS of T1a; (H) After PSM, OS of T1b; (I) After PSM, OS of T1c; (J) After PSM, BCSS of T1a; (K) After PSM, BCSS of T1b; (L) After PSM, BCSS of T1c.
